← All trials
NCT05604131
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 24, 2022
- Primary completion
- Nov 23, 2024
- Completion date
- Apr 30, 2025
- First posted
- Nov 3, 2022
- Last posted
- Dec 16, 2022
- Enrollment
- 60
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Indiana UniversityLead sponsor
- Indiana UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.